PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

 

Provided by NCCN in collaboration with Clinical Care Options

 

 

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
  • Identify patients based on molecular changes and previous therapy who are most likely to benefit from treatments with PARP inhibitors
  • Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
  • Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
Additional information
Supporters: 

Supported by educational grants from AstraZeneca and Pfizer.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
07/19/2019
Course expires: 
07/19/2020
Cost:
$0.00

Lee Schwartzberg, MD, FACP
Executive Director 
West Cancer Center
Germantown, Tennessee
Professor of Medicine
University of Tennessee Health Science Center
Memphis, Tennessee

Jennifer K. Litton, MD
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York


Disclosure of Relevant Financial Relationships

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners, and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2, and 6] by experts on the topics).

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty Disclosures

Jennifer K. Litton, MD, has disclosed that she has received funds for research support from AstraZeneca, EMD Serono, Genentech, GlaxoSmithKline, and Pfizer and has served on advisory boards (uncompensated) for AstraZeneca and Pfizer.

Mark E. Robson, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, BioMarin, and Medivation and consulting fees from AstraZeneca and McKesson.

Lee Schwartzberg, MD, FACP, has disclosed that he has served as a scientific advisor for Bristol-Myers Squibb Company and has received consulting fees/honoraria from Genentech, Genomic Health, and Pfizer.

Staff Disclosures

The activity planning staff listed below discloses no relevant financial relationships:
CCO: Timothy Quill, PhD; Gordon Kelley; Rachael M. Andrie, PhD; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CMP, CHCP

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD; Susan D. Darlow, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-9999-19-067-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/19/2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: